Omnicell — Third Quarter 2026 Earnings Summary

Omnicell reported third-quarter 2026 total revenues of $308 million, a 1% decrease from the prior year, while GAAP net income rose to $11 million and non-GAAP net income increased to $27 million. The company raised its full-year 2026 non-GAAP EBITDA guidance to a range of $187 million to $193 million and tightened its total revenue guidance to $1.225 billion to $1.231 billion. As of September 30, 2026, Omnicell held $315 million in cash and cash equivalents with $169 million in total debt. Management highlighted strong momentum for its next-generation Titan XT and OmniSphere platform as healthcare providers prioritize solutions to improve medication management efficiency.